查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004723

医药及医疗设备组合产品市场：2026-2032年全球市场预测（依产品类型、技术、剂型、治疗领域及最终用户划分）

Drug-Device Combination Products Market by Product Type, Technology, Dosage Form, Therapeutic Class, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，医药和医疗设备器材市场总值将达到 1,564.6 亿美元，到 2026 年将成长至 1,687 亿美元，到 2032 年将达到 2,746.1 亿美元，复合年增长率为 8.36%。

主要市场统计数据
基准年 2025 1564.6亿美元
预计年份：2026年 1687亿美元
预测年份 2032 2746.1亿美元
复合年增长率 (%) 8.36%

对联合疗法进行全面概述，将临床创新、监管细微差别和商业化要求置于现代开发生命週期中。

药理学与医疗设备工程的整合已发展成为一个重要的学术领域，它处于医疗创新和医疗保健服务的关键交汇点。药物-医疗设备复合物将活性成分与精心设计的递送系统结合，以增强治疗效果、提高用药依从性并催生新的治疗模式。本文概述了科学进步、以使用者为中心的设计以及监管要求相互交织的复杂图景，这既为製造商、临床医生和支付方带来了机会，也带来了挑战。

技术融合、监管完善以及对医疗保健服务期望的改变，如何重新定义联合疗法的开发方法和商业化策略？

变革性的技术、监管和医疗服务模式正在重塑医药和医疗设备的组合格局。智慧型设备功能的提升，例如嵌入式感测器、自动配药机制和数位化监测，正在催生新的用药依从性管理和远端医疗监测模式。这些技术进步正在加速从单一产品模式向整合式医疗生态系统的转变，在这个生态系统中，设备和软体透过数据驱动的洞察创造价值。

评估 2025 年贸易和关税变化对联合治疗筹资策略、製造本地化选择和供应链韧性的下游影响。

2025年推出的关税政策变化和贸易措施的累积影响正对联合治疗产品相关相关人员的采购、生产和分销策略产生重大影响。关键组件、原材料和成品的关税调整提高了全球价值链的成本可见性，迫使企业重新评估筹资策略和与供应商的合约条款。为此，许多企业正在加快多元化发展步伐，寻找替代供应商并实施双重采购安排，以降低单一来源依赖的风险并维持供应的连续性。

将产品类型、底层技术、剂型、治疗领域和最终用户环境连结起来的综合细分观点，指导策略优先排序。

一套精细的市场细分框架揭示了产品、技术、剂型、治疗领域和终端用户群如何影响整个复杂产品市场的策略和创新重点。基于产品类型，此市场研究涵盖药物释放型支架、吸入器、注射系统、预填充式注射器和注射笔、外用药物以及经皮贴片。注射系统类别进一步细分为自动注射器和无针注射器，二者分别面临不同的技术和使用者介面挑战。这种产品层面的差异不仅影响监管路径、包装要求和临床医生培训需求，也决定了在不影响药物稳定性的前提下，数位化功能在设备中的应用程度。

不同地区管理体制、采购实践和生产重点的差异如何影响联合疗法的开发和商业化策略？

区域趋势持续对监管预期、生产策略和复杂产品的商业性部署产生重大影响，各主要区域呈现不同的模式。在美洲，法规结构正在趋于统一，其核心是基于风险的评估和上市后监测，而采购机构则优先考虑临床证据和供应链透明度。这种情况正在推动能够显着改善用药依从性和治疗效果的解决方案的出现，从而支持将产品部署与培训和远端监测等服务相结合的经营模式。

製造商、供应商和服务供应商之间的合作联盟、对平台的投资以及产能扩张如何重新定义组合产品生态系统中的竞争优势。

产品开发商、供应商和服务供应商之间的竞争呈现出平台创新、策略伙伴关係和能力建构投资三者融合的趋势。成熟的製药公司和医疗设备製造商正日益建立合作关係，将配方专业知识与器材工程相结合，并常常围绕临床疗效和通用的商业目标来协调奖励。同时，专注于医疗技术的专业公司和科技Start-Ups则致力于感测器整合、注射装置小型化或穿戴式黏合系统等细分领域，并透过授权和收购来拓展产品系列。

可操作的跨职能策略和战术性投资，能够降低开发风险，加强部署途径，并保持竞争优势。

致力于将创新转化为永续市场成功的产业领导者应制定一套协作且切实可行的策略，协调科学、监管、生产和商业职能。首先，他们应从研发早期阶段就引入跨部门管治，使配方要求与器材工程、人体工学和软体检验需求保持一致。这种整合的管治模式能够减少返工，使监管申报更加清晰，并加快就对支付方和临床医生至关重要的临床终点达成共识。

透过高度透明的混合方法研究途径，结合专家访谈、有针对性的二手研究和三角检验，检验了研究结果的有效性，同时也承认了调查方法的局限性。

本分析所依据的研究结合了定性和定量方法，旨在提取可操作的洞见，同时保持方法论的严谨性。关键资料来源包括与跨学科专家（如临床医生、法规专家、采购经理和製造工程师）进行的结构化访谈，这些访谈提供了关于营运限制和市场推广驱动因素的真实观点。此外，还组织了有针对性的专家小组，以检验新出现的主题，并检验策略建议在不同产品类型和地区的适用性。

简洁地总结了整合开发、供应链敏捷性和实证商业化是联合治疗成功的核心要求。

总之，药品和医疗设备的组合在现代医疗保健中占据着动态且重要的策略地位，具有提高治疗效果、病患依从性和系统性疗效的潜力。最显着的变化发生在技术整合、监管调整和不断演进的医疗服务模式的交会点。为了在这种环境下取得成功，製造商必须采用整合开发模式，投资于供应链的柔软性，并优先产生能够证明其临床和经济价值的证据。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：医药及医疗设备组合产品市场：依产品类型划分

  • 药物释放型支架
  • 吸入器
  • 注射系统
    • 自动注射器
    • 无针注射器
  • 预填充式注射器和注射笔
  • 外用药物
  • 经皮吸收贴剂

第九章：医药及医疗设备组合产品市场：依技术划分

  • 先进的释放技术
  • 可生物降解技术
  • 传统医疗设备与製药联合技术
  • 智慧型装置技术
    • 自动化管理
    • 数位监控

第十章：以剂型分類的药品和医疗设备复杂产品市场

  • 液体
  • 半固态製剂
    • 奶油
    • 软膏
    • 粉末
  • 固态剂量
    • 胶囊
    • 药片

第十一章：依治疗领域分類的药品和医疗设备组合产品市场

  • 循环系统药物
  • 糖尿病/内分泌学
  • 荷尔蒙补充疗法
  • 抗癌药物
    • 化疗
    • 参与式癌症治疗
  • 疼痛管理

第十二章：医药及医疗设备组合产品市场：依最终用户划分

  • 门诊手术中心
  • 居家医疗设施
  • 医院和诊所
  • 专科诊所

第十三章：医药及医疗设备组合产品市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：医药及医疗设备综合产品市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：药品和医疗设备综合产品市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国药品和医疗设备综合产品市场

第十七章：中国医药医疗设备综合产品市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • B. Braun SE
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Braile Biomedica
  • Cardinal Health, Inc.
  • CODAN Companies
  • Cook Group Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi
  • ICU Medical, Inc.
  • InSitu Technologies Inc.
  • JMS North America Corporation
  • Lepu Medical Technology Company
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Novartis AG
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • SOOIL Developments Co., Ltd.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Group
  • Viatris Inc.
  • WL Gore & Associates Inc.
Product Code: MRR-742BD517D8D5

The Drug-Device Combination Products Market was valued at USD 156.46 billion in 2025 and is projected to grow to USD 168.70 billion in 2026, with a CAGR of 8.36%, reaching USD 274.61 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 156.46 billion
Estimated Year [2026] USD 168.70 billion
Forecast Year [2032] USD 274.61 billion
CAGR (%) 8.36%

A comprehensive orientation to combination therapeutics that situates clinical innovation, regulatory nuance, and commercialization imperatives within a modern development lifecycle

The integration of pharmacology and device engineering has evolved into a defining discipline at the intersection of medical innovation and healthcare delivery. Drug-device combination products bring together active pharmaceutical ingredients and engineered delivery systems to enhance therapeutic performance, improve adherence, and enable new modes of care. This introduction frames a multidimensional landscape in which scientific advances, user-centered design, and regulatory expectations converge to create both opportunity and complexity for manufacturers, clinicians, and payers.

Recent years have seen a shift from incremental enhancements toward systems-level solutions that embed sensors, connectivity, and data analytics into delivery platforms. Consequently, development teams must orchestrate expertise spanning formulation science, materials engineering, software development, human factors, and quality systems. At the same time, regulatory pathways have adapted to account for hybrid product characteristics, emphasizing demonstration of safety and efficacy across both device and drug components, as well as post-market surveillance strategies tailored to combination-specific risks.

From a commercialization perspective, payers and procurement channels are increasingly focused on real-world performance and total cost of care implications, which can accelerate adoption where clinical and economic value are clearly demonstrated. Manufacturers therefore find that early alignment between clinical development, regulatory strategy, and market access planning is essential. This introduction sets the stage for a deeper analysis of transformative shifts, tariff-driven supply chain impacts, segmentation nuances, regional dynamics, and actionable steps leaders can take to succeed in this rapidly evolving domain.

How converging technology, regulatory refinement, and shifting care delivery expectations are redefining development approaches and commercialization strategies in combination therapeutics

The landscape for drug-device combination products is being reshaped by a confluence of technological, regulatory, and care-delivery forces that together are driving transformative change. Advances in smart device capabilities-such as embedded sensors, automatic dosing mechanisms, and digital monitoring-are enabling new models of adherence management and remote therapeutic monitoring. These technological enhancements are fostering a move from discrete product offerings toward integrated care ecosystems in which devices and software generate value through data-driven insights.

Regulatory authorities are responding by refining guidance that addresses hybrid product evaluation, cybersecurity expectations, and post-market data collection, thereby elevating the bar for integrated validation and lifecycle management. Concurrently, manufacturers are pursuing modular design philosophies and platform approaches to accelerate iteration while managing regulatory complexity. Supply chain resilience and manufacturing flexibility have become strategic priorities, prompting investments in nearshoring, multi-sourcing, and process automation to minimize disruption and protect time-to-market.

Clinician and patient expectations are also evolving: user-centric design, simplified administration, and demonstrable improvements in patient outcomes are central to adoption. Payers increasingly demand evidence of cost-effectiveness and real-world utility, which incentivizes manufacturers to incorporate health economics and outcomes research earlier in development. As a result, the most successful organizations are those that align R&D, regulatory, commercial, and manufacturing functions around a shared, data-informed value proposition that supports scalable, sustainable deployment of combination therapies.

Evaluating the downstream consequences of 2025 trade and tariff shifts on sourcing strategies, manufacturing localization choices, and supply chain resilience for combination therapies

The cumulative impact of tariff policy changes and trade measures introduced in 2025 has had meaningful implications for the procurement, manufacturing, and distribution strategies of combination product stakeholders. Tariff adjustments on critical components, raw materials, and finished goods have heightened cost visibility across global value chains, prompting companies to reassess sourcing strategies and contractual terms with suppliers. In response, many organizations accelerated diversification efforts, identifying alternate suppliers and dual-sourcing arrangements to mitigate single-origin exposure and maintain continuity of supply.

Beyond direct input costs, tariffs have influenced decisions around geographic placement of critical manufacturing activities and investment in localized assembly or final-stage manufacturing. These shifts are often accompanied by careful analysis of regulatory compliance across jurisdictions, given that relocating production can entail new registration, inspection, and quality system obligations. Firms have therefore balanced the cost impact of tariffs against the regulatory complexity and lead time associated with establishing compliant manufacturing in new regions.

Importantly, tariff-driven pressures have incentivized tighter collaboration across procurement, regulatory, and product teams to ensure that adjustments in sourcing do not compromise material compatibility, device performance, or drug stability. Industry response has included renegotiated supplier agreements with built-in contingency clauses, expanded use of contractual hedging strategies, and targeted investments in supply chain visibility technologies. Taken together, these responses reflect a pragmatic effort to preserve product integrity and market access while adapting to an altered trade environment.

An integrated segmentation perspective connecting product types, enabling technologies, dosage forms, therapeutic classes, and end-user environments to guide strategic prioritization

A nuanced segmentation framework illuminates how product, technology, dosage form, therapeutic focus, and end-user context shape strategy and innovation priorities across the combination product landscape. Based on Product Type, the market is studied across Drug-Eluting Stents, Inhalers, Injector Systems, Prefilled Syringes & Pens, Topical Medicines, and Transdermal Patches; the Injector Systems category is further examined across Auto-Injectors and Needle-Free Injectors, each presenting different engineering and user-interface challenges. This product-level differentiation influences regulatory pathways, packaging requirements, and clinician training needs, and it also determines the extent to which devices can incorporate digital features without disrupting drug stability.

Based on Technology, the market is studied across Advanced Release Technologies, Biodegradable Technology, Conventional Device-Drug Technology, and Smart Device Technologies; the Smart Device Technologies subgroup is further analyzed for Automatic Dosing and Digital Monitoring capabilities. Adoption of advanced release and biodegradable platforms often hinges on material science innovations and compatibility testing, while smart technologies demand robust software verification, cybersecurity measures, and data interoperability strategies to support clinical workflows and reimbursement claims.

Based on Dosage Form, the market is studied across Liquid Dosage Forms, Semi-Solid Dosage Forms, and Solid Dosage Forms; the Semi-Solid Dosage Forms are further explored through Creams, Ointments, and Powders, and the Solid Dosage Forms are further considered across Capsules and Tablets. Dosage form selection affects stability, device design, and patient administration protocols, and it imposes specific analytical and quality control requirements. Based on Therapeutic Class, the market is studied across Cardiovascular Medications, Diabetes & Endocrinology, Hormonal Replacement Therapy, Oncology Drugs, and Pain Management; the Oncology Drugs subset is further categorized into Chemotherapy and Participatory Oncology Treatment, reflecting divergent safety profiles and monitoring needs. Finally, Based on End-User, the market is studied across Ambulatory Surgical Centers, Homecare Settings, Hospitals and Clinics, and Specialty Clinics, which together define differing operational constraints, training resources, and procurement models. Integrating these segmentation dimensions helps stakeholders prioritize product design trade-offs, regulatory strategy, and market access efforts according to the technical, clinical, and delivery-context nuances that matter most.

How divergent regulatory regimes, procurement behaviors, and manufacturing priorities across major regions shape development and commercialization strategies for combination therapeutics

Regional dynamics continue to exert strong influence over regulatory expectations, manufacturing strategies, and commercial deployment of combination products, with distinct patterns emerging across major geographies. In the Americas, regulatory frameworks are increasingly harmonized around risk-based evaluation and post-market surveillance expectations, while purchaser institutions emphasize clinical evidence and supply chain visibility. These conditions favor solutions that demonstrate measurable improvements in adherence and outcomes, and they support commercial models that pair product deployment with services such as training and remote monitoring.

Across Europe, Middle East & Africa, diverse regulatory regimes and procurement modalities require adaptive market access strategies that account for national reimbursement mechanisms and localized clinical guidelines. In this complex environment, manufacturers often prioritize region-specific regulatory expertise and targeted pilot programs to establish clinical value and payer acceptance. Moreover, the emphasis on sustainability and circular economy principles in parts of this region can influence material selection and end-of-life planning for device components.

The Asia-Pacific region presents a combination of rapid adoption potential and heterogeneity in regulatory maturity. Several markets in this region are expediting approvals for innovative delivery platforms while simultaneously building local manufacturing capability. These dynamics make Asia-Pacific attractive for companies seeking scale and cost efficiencies, but they also demand careful navigation of intellectual property protection, localization requirements, and partnership models with local distributors and contract manufacturers. Taken together, regional insights underscore the importance of tailoring regulatory, manufacturing, and commercial strategies to local realities while maintaining global standards for quality and evidence generation.

How collaborative alliances, platform investments, and capability expansion among manufacturers, suppliers, and service providers are redefining competitive advantage in combination product ecosystems

Competitive behavior among product developers, suppliers, and service providers is characterized by a blend of platform innovation, strategic partnerships, and capability-building investments. Established pharmaceutical firms and device manufacturers are increasingly entering into collaborative arrangements to combine formulation expertise with device engineering, often structuring alliances to align incentives around clinical outcomes and shared commercial goals. At the same time, specialized medtech companies and technology startups focus on niche capabilities-such as sensor integration, injection mechanism miniaturization, or wearable adhesion systems-that can be licensed or acquired to complete broader product portfolios.

Supply chain and manufacturing players are differentiating through investments in scalable, compliant assembly capabilities and quality management systems tailored for combination products. Contract development and manufacturing organizations are expanding service offerings to include integrated testing, stability programs, and human factors engineering support to reduce time-to-market for sponsors. Additionally, software vendors and digital health specialists are forging relationships with device and drug developers to provide data platforms, analytics, and interoperability solutions that support remote monitoring and adherence programs.

Regulatory consultants and clinical research organizations are also adapting, offering end-to-end support for regulatory strategy, clinical validation, and post-market evidence generation specific to hybrid product requirements. Across this ecosystem, successful companies demonstrate a capacity to manage complex multidisciplinary programs, deploy capital selectively to bridge capability gaps, and structure commercial models that highlight demonstrable improvements in patient outcomes and system-level efficiencies.

Practical cross-functional strategies and tactical investments that enable organizations to reduce development risk, strengthen adoption pathways, and sustain competitive differentiation

Industry leaders seeking to translate innovation into sustained market success should pursue a set of coordinated, actionable strategies that align scientific, regulatory, manufacturing, and commercial functions. First, embed cross-functional governance early in development to reconcile formulation requirements with device engineering, human factors, and software validation needs. This integrated governance model reduces rework, enables clearer regulatory submissions, and accelerates alignment on clinical endpoints that matter to payers and clinicians.

Second, prioritize supply chain resilience by diversifying critical component sourcing and investing in visibility tools that track provenance and quality attributes. Where feasible, evaluate nearshoring or flexible manufacturing arrangements for final assembly to shorten lead times and simplify regulatory logistics. Third, incorporate digital features and data strategies that augment therapeutic value while ensuring robust cybersecurity, privacy compliance, and interoperability with existing clinical systems. Early engagement with regulators on digital elements can clarify expectations and reduce downstream uncertainty.

Fourth, adopt value-based evidence generation approaches that combine clinical trials with pragmatic, real-world outcome studies to demonstrate both clinical efficacy and economic impact. Align commercial models accordingly, offering bundled solutions that pair product access with training, support services, and data-driven programs to improve adherence. Finally, cultivate strategic partnerships and targeted M&A to fill capability gaps rather than trying to internalize every technical domain. By focusing on these priorities, leaders can reduce development risk, enhance adoption, and create defensible value propositions in an increasingly integrated therapeutic environment.

A transparent mixed-methods research approach combining expert interviews, targeted secondary analysis, and triangulation to validate insights while acknowledging methodological limitations

The research behind this analysis combines qualitative and quantitative methods designed to surface actionable insights while maintaining methodological rigor. Primary inputs included structured interviews with cross-disciplinary subject-matter experts, including clinical practitioners, regulatory specialists, procurement leaders, and manufacturing engineers, which provided real-world perspectives on operational constraints and adoption drivers. These interviews were supplemented by targeted expert panels to validate emergent themes and test the applicability of strategic recommendations across different product types and regions.

Secondary research drew on peer-reviewed literature, regulatory guidance documents, standards publications, and company disclosures to build a factual baseline around technical capabilities, safety considerations, and policy trends. Data triangulation techniques were applied to reconcile differing viewpoints and to ensure that conclusions reflect convergent evidence rather than isolated observations. Where appropriate, case studies of recent product launches and regulatory decisions were analyzed to extract lessons on go-to-market sequencing, evidence generation, and post-market surveillance.

Quality assurance procedures included independent review by methodological peers, consistency checks across data sources, and sensitivity analysis to identify areas of uncertainty. Limitations of the approach are acknowledged, particularly regarding rapidly evolving technology domains and jurisdiction-specific regulatory actions that may change after the analysis period. To mitigate these limitations, readers are encouraged to supplement the findings with contemporaneous regulatory updates and localized expert input when applying the recommendations to specific program decisions.

A succinct synthesis emphasizing integrated development, supply chain agility, and evidence-based commercialization as the core imperatives for combination therapy success

In conclusion, drug-device combination products occupy a dynamic and strategically important space in modern healthcare, offering the potential to improve therapeutic efficacy, patient adherence, and system-level outcomes. The most consequential shifts are occurring at the intersection of technology integration, regulatory adaptation, and changing care-delivery norms. Success in this environment requires manufacturers to adopt integrated development models, to invest in supply chain flexibility, and to prioritize evidence generation that demonstrates both clinical and economic value.

Stakeholders must also navigate the operational realities introduced by recent trade measures and evolving regional requirements, aligning sourcing and manufacturing choices with regulatory readiness and commercial objectives. Market participants who proactively design for regulatory compliance, user-centered deployment, and robust post-market data collection will be better positioned to secure adoption among clinicians and payers. Collaboration across the ecosystem-linking specialized technology providers, contract manufacturers, clinical networks, and reimbursement experts-remains a central enabler for accelerating innovation while managing risk.

Ultimately, informed decision-making grounded in multidisciplinary evidence and adaptive strategy will determine which organizations translate scientific advances into widely adopted combination therapies. The themes explored in this summary point to a pragmatic path forward: integrate capabilities early, validate value rigorously, and structure commercial models that deliver measurable benefits to patients and healthcare systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug-Device Combination Products Market, by Product Type

  • 8.1. Drug-Eluting Stents
  • 8.2. Inhalers
  • 8.3. Injector Systems
    • 8.3.1. Auto-Injectors
    • 8.3.2. Needle-Free Injectors
  • 8.4. Prefilled Syringes & Pens
  • 8.5. Topical Medicines
  • 8.6. Transdermal Patches

9. Drug-Device Combination Products Market, by Technology

  • 9.1. Advanced Release Technologies
  • 9.2. Biodegradable Technology
  • 9.3. Conventional Device-Drug Technology
  • 9.4. Smart Device Technologies
    • 9.4.1. Automatic Dosing
    • 9.4.2. Digital Monitoring

10. Drug-Device Combination Products Market, by Dosage Form

  • 10.1. Liquid Dosage Forms
  • 10.2. Semi-Solid Dosage Forms
    • 10.2.1. Creams
    • 10.2.2. Ointments
    • 10.2.3. Powders
  • 10.3. Solid Dosage Forms
    • 10.3.1. Capsules
    • 10.3.2. Tablets

11. Drug-Device Combination Products Market, by Therapeutic Class

  • 11.1. Cardiovascular Medications
  • 11.2. Diabetes & Endocrinology
  • 11.3. Hormonal Replacement Therapy
  • 11.4. Oncology Drugs
    • 11.4.1. Chemotherapy
    • 11.4.2. Participatory Oncology Treatment
  • 11.5. Pain Management

12. Drug-Device Combination Products Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Homecare Settings
  • 12.3. Hospitals and Clinics
  • 12.4. Specialty Clinics

13. Drug-Device Combination Products Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug-Device Combination Products Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug-Device Combination Products Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drug-Device Combination Products Market

17. China Drug-Device Combination Products Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. B. Braun SE
  • 18.8. Baxter International Inc.
  • 18.9. Becton, Dickinson and Company
  • 18.10. BIOTRONIK SE & Co. KG
  • 18.11. Boston Scientific Corporation
  • 18.12. Braile Biomedica
  • 18.13. Cardinal Health, Inc.
  • 18.14. CODAN Companies
  • 18.15. Cook Group Incorporated
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. Fresenius Kabi
  • 18.18. ICU Medical, Inc.
  • 18.19. InSitu Technologies Inc.
  • 18.20. JMS North America Corporation
  • 18.21. Lepu Medical Technology Company
  • 18.22. Medtronic PLC
  • 18.23. MicroPort Scientific Corporation
  • 18.24. Novartis AG
  • 18.25. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 18.26. SOOIL Developments Co., Ltd.
  • 18.27. Stryker Corporation
  • 18.28. Teleflex Incorporated
  • 18.29. Terumo Group
  • 18.30. Viatris Inc.
  • 18.31. W. L. Gore & Associates Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 212. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 217. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 218. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 245. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 251. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 252. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 256. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 261. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 262. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC C